
Sarepta backs down and pauses Elevidys shipments
The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed to the regulator's request to temporarily suspend shipments of the Duchenne muscular dystrophy (DMD) gene therapy. The FDA …